Insider Selling: Vaxxinity, Inc. (NASDAQ:VAXX) Major Shareholder Sells $804,763.08 in Stock
Insider Selling: Vaxxinity, Inc. (NASDAQ:VAXX) Major Shareholder Sells $804,763.08 in Stock
Vaxxinity, Inc. (NASDAQ:VAXX – Get Rating) major shareholder Movers Lab Fund I. Lp Prime sold 270,964 shares of the stock in a transaction that occurred on Thursday, December 1st. The shares were sold at an average price of $2.97, for a total transaction of $804,763.08. Following the completion of the sale, the insider now directly owns 9,180,710 shares in the company, valued at $27,266,708.70. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Major shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.
纳斯达克(股票代码:VAXX-GET Rating)大股东摩沃斯实验室基金I.LP Prime在12月1日(星期四)的交易中出售了270,964股该股。这些股票的平均价格为2.97美元,总成交额为804,763.08美元。出售完成后,这位内部人士现在直接拥有该公司9,180,710股,价值27,266,708.70美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可在此超链接。持有公司10%以上股份的大股东必须披露他们与美国证券交易委员会的交易。
Vaxxinity Trading Up 0.5 %
Vaxxity交易上涨0.5%
Shares of NASDAQ:VAXX opened at $2.00 on Thursday. Vaxxinity, Inc. has a 52 week low of $1.26 and a 52 week high of $10.57. The company's 50 day moving average is $1.73 and its two-hundred day moving average is $2.14. The company has a current ratio of 3.33, a quick ratio of 3.33 and a debt-to-equity ratio of 0.12. The company has a market cap of $252.11 million and a PE ratio of -1.61.
纳斯达克:瓦克斯周四开盘报2.00美元。Vaxxity,Inc.的52周低点为1.26美元,52周高位为10.57美元。该公司的50日移动均线切入位在1.73美元,200日移动均线切入位在2.14美元。该公司的流动比率为3.33,速动比率为3.33,债务权益比率为0.12。该公司市值为2.521亿美元,市盈率为-1.61。
Institutional Investors Weigh In On Vaxxinity
机构投资者参与Vaxxity
A number of large investors have recently modified their holdings of VAXX. Bank of America Corp DE grew its position in shares of Vaxxinity by 7,829.0% in the 1st quarter. Bank of America Corp DE now owns 15,858 shares of the company's stock valued at $68,000 after buying an additional 15,658 shares during the last quarter. Hollencrest Capital Management purchased a new position in shares of Vaxxinity in the 2nd quarter valued at $31,000. Clarius Group LLC purchased a new position in shares of Vaxxinity in the 2nd quarter valued at $31,000. Truist Financial Corp purchased a new position in shares of Vaxxinity in the 2nd quarter valued at $33,000. Finally, First Republic Investment Management Inc. purchased a new position in shares of Vaxxinity in the 3rd quarter valued at $394,000. 20.73% of the stock is owned by hedge funds and other institutional investors.
一些大型投资者最近修改了对VAXX的持股。美国银行DE在第一季度将其在Vaxxity股票的头寸增加了7829.0%。美国银行DE目前持有15,858股该公司股票,价值68,000美元,此前该公司在上一季度又购买了15,658股。Hollencrest Capital Management在第二季度购买了Vaxxity的新头寸,价值3.1万美元。Clarius Group LLC在第二季度购买了Vaxxity的新头寸,价值31,000美元。TRUIST FINANCIAL CORPORATION在第二季度购买了价值33,000美元的Vaxxity新股头寸。最后,First Republic Investment Management Inc.在第三季度购买了价值39.4万美元的Vaxxity新股票头寸。20.73%的股票由对冲基金和其他机构投资者持有。
About Vaxxinity
关于Vaxxity
Vaxxinity, Inc, a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD.
Vaxxity,Inc.是一家生物技术公司,专注于在美国神经学和冠状病毒领域开发供人类使用的候选产品。该公司致力于开发针对大脑中有毒形式的聚集淀粉样蛋白b来对抗阿尔茨海默病(AD)的UB-311,该药物处于第二阶段临床试验;UB-312针对大脑中有毒形式的聚集a-突触核蛋白,以对抗帕金森病和其他共核疾病,例如处于第一阶段临床试验的路易体痴呆和多系统萎缩;以及一种针对包括阿尔茨海默病在内的各种神经退行性疾病的候选抗tau产品。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Vaxxinity (VAXX)
- Are Investors Hearing The End Of Spotify's Downtrend?
- The Question of a Fed Pivot Isn't If, It's When, Here's Why
- Top 10 Searched Stocks on MarketBeat All-Access
- 3 Dividend Kings With Royally Good Upside
- Institutions Sell The Rallies In Toll Brothers Stock
- 免费获取StockNews.com关于Vaxxity的研究报告(VAXX)
- 投资者是否听到了Spotify下跌趋势的终结?
- 美联储轴心的问题不是是否,而是何时,这是为什么
- 在MarketBeat All-Access上搜索的前10名股票
- 王室利好的3个股息之王
- 机构抛售Toll Brothers股票的涨势
Receive News & Ratings for Vaxxinity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxxinity and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Vaxxity Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Vaxxity和相关公司的最新新闻和分析师评级的每日简要摘要。